+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-5: Hela cells, A549 cells, MCF7 cells, human liver cancer tissue, Human lung cancer tissue, Primary antibody: P07936(RPN1 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07936(RPN1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07936(RPN1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The eukaryotic initiation factor 4G1 (EIF4G1) is a critical scaffolding protein involved in cap-dependent translation initiation. As a core component of the eIF4F complex, EIF4G1 interacts with eIF4E (cap-binding protein), eIF4A (RNA helicase), and poly(A)-binding protein (PABP), facilitating the circularization of mRNA and recruitment of ribosomes. This process is essential for synthesizing proteins under normal cellular conditions and during stress responses. Dysregulation of EIF4G1 has been implicated in various pathologies, including cancer, neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s), and viral infections, where pathogens often hijack the host translation machinery.

Antibodies targeting EIF4G1 are widely used in research to study translational regulation, stress granule dynamics, and virus-host interactions. They enable detection of EIF4G1 expression levels, post-translational modifications (e.g., phosphorylation), and interactions with other proteins through techniques like Western blotting, immunoprecipitation, and immunofluorescence. Commercially available EIF4G1 antibodies are typically raised against specific epitopes, such as the N-terminal or C-terminal regions, and validation includes testing for cross-reactivity with homologous proteins like EIF4G2.

Recent studies highlight EIF4G1's role in disease mechanisms, such as its overexpression in cancers promoting tumor progression, or its aggregation in neurodegenerative conditions. These findings underscore the importance of EIF4G1 antibodies as tools for both basic research and therapeutic target discovery.